S&P 500 Healthcare Sector SEC Filings — March 03, 2026

03-03-2026

Protagenic Therapeutics, Inc. appointed William (Bill) Nichols, Jr., age 51, as President effective February 3, 2026. Mr. Nichols brings senior commercial leadership experience from bluebird bio, Dova Pharmaceuticals (now Sobi), and Bristol-Myers Squibb. Compensation includes an annual base salary of $350,000, eligibility for a 40% target bonus, and an option grant equal to approximately 1.0% of the company's fully diluted shares.

• ·No arrangements or understandings with other persons for Mr. Nichols' selection as officer.
• ·No family relationships between Mr. Nichols and any directors or executive officers.
• ·No transactions involving Mr. Nichols requiring disclosure under Item 404(a) of Regulation S-K.

03-03-2026

News Corporation disclosed under Item 8.01 that, as part of its ongoing $1 billion stock repurchase program for Class A and Class B common stock, it provided daily transaction information to the Australian Securities Exchange (ASX) as required. Exhibits 99.1 and 99.2 contain the specific disclosures made on respective dates noted therein. The filing includes forward-looking statements on potential repurchases, subject to market conditions and other factors.

• ·Date of earliest event reported: March 2, 2026
• ·Filing Date: March 3, 2026
• ·Securities registered: Class A Common Stock (NWSA, par value $0.01) and Class B Common Stock (NWS, par value $0.01) on Nasdaq Global Select Market
• ·Company address: 1211 Avenue of the Americas, New York, New York 10036
• ·Registrant details: Delaware incorporation, Commission File Number 001-35769, IRS Employer ID 46-2950970

03-03-2026

CalciMedica reported a net loss of $29.6M for 2025, up from $13.7M in 2024, driven by $16.9M worse other income/expense including fair value adjustments and interest on a new promissory note, though R&D expenses rose modestly to $15.2M (+5%) and G&A fell to $7.9M (-19%). Cash position stood at $13.0M, sufficient into Q4 2026, amid clinical updates including no drug-related toxicity in the discontinued Phase 2 KOURAGE AKI trial and plans to finalize Auxora pivotal program design in AP during 1H 2026. CM5480 preclinical data in PAH was published, with IND anticipated in 2027.

• ·Phase 2 KOURAGE trial discontinued in Jan 2026 due to IDMC-recommended reevaluation of mortality imbalance, possibly from baseline disease severity; FDA discussions planned for Q2 2026.
• ·High-dose Auxora in CARPO trial: 100% reduction in new-onset severe respiratory failure (p<0.05), stratified win ratio 1.640 (p<0.05); no drug-related TESAEs or deaths.
• ·Total assets declined to $13.6M from $19.8M; stockholders' equity turned negative at -$6.6M from +$14.4M.

03-03-2026

Roivant Sciences Ltd. announced via press release that the U.S. FDA has accepted the New Drug Application (NDA) for brepocitinib, filed by its subsidiary Priovant Therapeutics, for the treatment of dermatomyositis and granted Priority Review. This regulatory milestone advances the potential approval timeline for the drug. No financial or comparative performance data was disclosed.

• ·Filing date: March 3, 2026
• ·Press release date: March 3, 2026
• ·U.S. FDA granted Priority Review to the NDA

03-03-2026

The Cigna Group announced David M. Cordani will retire as CEO effective July 1, 2026, transitioning to Executive Chair, with President and COO Brian Evanko succeeding him as CEO and joining the Board. Under Cordani's nearly 17-year tenure, the company grew from serving 46 million customers with $18B annual revenue to 180 million customer relationships and $275B revenue, delivering over 750% total shareholder return. The company reaffirmed its 2026 financial outlook with no changes indicated.

• ·Brian Evanko has nearly 30 years with the company.
• ·David M. Cordani has served nearly 17 years as CEO.
• ·Leadership transition period through July 1, 2026.

03-03-2026

Civeo reported Q4 2025 revenues of $161.6M, up 7% YoY from $151.0M, with Adjusted EBITDA rising 90% to $21.7M, driven by Australian growth (+9% revenues) and Canadian margin improvement (from -13% to 8%). However, full-year 2025 revenues declined 6% YoY to $638.8M from $682.1M amid Canadian occupancy pressures, resulting in a wider net loss of $20.1M versus $17.1M in 2024, despite Adjusted EBITDA growth to $88.2M (+10% YoY). The company repurchased 2.3M shares for $53.6M (17% of shares outstanding), nearing completion of its initial 20% repurchase authorization, and announced a new 10% authorization.

• ·Full year 2026 guidance: revenues $650M-$700M, Adjusted EBITDA $85M-$90M, capex $25M-$30M.
• ·Net leverage ratio of 1.9x as of Dec 31, 2025.
• ·Q4 2025 free cash flow $15.3M (vs $2.1M in Q4 2024).
• ·Conference call scheduled for March 3, 2026 at 11:00 a.m. ET.

03-03-2026

Prime Medicine reported FY2025 financial results showing revenue growth of 55% YoY to $4.6M, driven by collaboration revenue, while R&D expenses increased 3.5% to $160.6M, G&A rose 4.3% to $52.3M, and net loss widened 3% YoY to $201.1M amid higher license costs and facility expenses offset by workforce reductions. Cash, cash equivalents, investments, and restricted cash totaled $191.4M as of Dec 31, 2025, down 6% from $204.5M prior year but providing runway into 2027. Pipeline progress includes planned IND/CTA for Wilson Disease in 1H2026 and AATD mid-2026, with initial data in 2027, and BLA submission for PM359 in CGD following FDA alignment.

• ·Total assets $342.7M as of Dec 31, 2025 (up from $297.5M YoY)
• ·Total liabilities $221.9M as of Dec 31, 2025 (up from $144.4M YoY)
• ·Collaboration revenue - related party $4.6M FY2025 (vs $1.6M FY2024)
• ·Net loss per share $(1.35) FY2025 (improved from $(1.65) FY2024)

03-03-2026

MVB Financial Corp., holding company for MVB Bank Inc., redeemed all $40.0 million aggregate principal amount of its 4.25% Fixed-to-Floating Rate Subordinated Notes due 2030 on March 2, 2026, which qualified as Tier 2 capital and bore 7.67% interest at redemption. The redemption was funded by a $20.0 million draw on its revolving line of credit and cash on hand. No other period-over-period metrics or performance changes were reported.

• ·Redemption date: March 2, 2026; Filing date: March 3, 2026
• ·Notes structured to qualify as Tier 2 capital for regulatory purposes

03-03-2026

A shareholder in COCA-COLA EUROPACIFIC PARTNERS plc (CCEP) has crossed or reached a threshold, resulting in a holding of 37.07% of voting rights attached to shares (with 0% through financial instruments), equivalent to 166,128,987 total voting rights. No position from previous notification is provided, indicating this may be a new or significantly updated stake.

• ·Filing date: March 03, 2026
• ·Filing type: 6-K (Foreign Issuer Report)

03-03-2026

FS Specialty Lending Fund filed an 8-K on March 3, 2026, announcing under Item 7.01 that a presentation containing financial and operating information will be made available in the Investor Relations section of its website (https://www.fssl.futurestandard.com/) after market close on March 3, 2026. The filing includes standard forward-looking statements disclaimers but discloses no specific financial metrics, amounts, or performance data. No period-over-period comparisons or quantitative details are provided in the document itself.

• ·Commission File Number: 811-24080
• ·I.R.S. Employer Identification No.: 33-4638504
• ·Principal executive offices: 3025 JFK Boulevard, OFC 500, Philadelphia, Pennsylvania 19104

03-03-2026

Pulse Biosciences, Inc. posted an updated investor presentation on its website on March 3, 2026, disclosing certain summary financial information, a description of its next-generation nPulse cardiac catheter under development, and a strengthened focus on EP cardio ablation product and clinical development following unprecedented clinical outcomes data in the Company's EU feasibility study. The Investor Deck is attached as Exhibit 99.1 and available at www.pulsebiosciences.com under 'Investors,' and may be used in presentations to investors and analysts. The information is summary only, as of March 2026, and subject to risks and forward-looking statements.

03-03-2026

First Citizens BancShares, Inc. issued and sold $500M aggregate principal amount of its 4.869% Fixed-to-Floating Rate Senior Notes due 2032 on March 3, 2026, in a public offering. The notes were issued pursuant to a senior base indenture dated March 12, 2025, as supplemented, and an underwriting agreement dated February 25, 2026, with J.P. Morgan Securities LLC, BofA Securities, Inc., and Wells Fargo Securities, LLC as representatives. No period-over-period financial comparisons are provided in the filing.

• ·Registration Statement on Form S-3 filed August 14, 2024 (File No. 333-281553)
• ·Prospectus Supplement dated February 25, 2026, filed February 26, 2026
• ·Senior Base Indenture dated March 12, 2025
• ·Second Supplemental Indenture dated March 3, 2026

03-03-2026

BrightView Holdings, Inc. held its 2026 Annual Meeting of Stockholders on March 3, 2026, electing eight directors for common stock (e.g., Dale A. Asplund with 131.1M votes for and Jane Okun Bomba with 132.2M votes for) and two directors (Kurtis Barker and Joshua Goldman) for Series A Convertible Preferred Stock with unanimous 500,000 votes for each. While all directors received majority support, significant votes were withheld for James R. Abrahamson (23.5M withheld) and Paul E. Raether (10.3M withheld). Stockholders ratified Deloitte & Touche LLP as the independent auditor for fiscal 2026 with overwhelming support of 139.0M votes for versus 206K against.

• ·Proxy Statement filed with SEC on January 15, 2026
• ·Directors elected for one-year term expiring at 2027 Annual Meeting
• ·5,348 abstentions on auditor ratification

03-03-2026

Ventyx Biosciences, Inc. held a special shareholder meeting on March 3, 2026, where Proposal 1 to approve the Merger Agreement with Eli Lilly and Company received overwhelming support with 44,176,785 votes FOR (96.4% of votes cast) versus 1,572,592 AGAINST out of 45,810,746 shares present or by proxy. Proposal 2 on advisory executive compensation approval also passed with 43,789,693 FOR (95.6%). As of the January 21, 2026 record date, 71,760,778 common shares were outstanding.

• ·Merger Agreement dated January 7, 2026; special meeting at 10:00 a.m. Pacific time on March 3, 2026.
• ·Proxy statement dated February 2, 2026, amended February 23, 2026.
• ·Proposal 3 (adjournment) rendered moot and not presented.

03-03-2026

Babcock & Wilcox Enterprises, Inc. executed the Tenth Amendment to its Credit Agreement and Security Agreement with Axos Bank on February 25, 2026, amending the borrowing base to 90% of Eligible Trade Receivables, setting NOLV Percentage at 30.78%, extending the Maturity Date to January 18, 2028, and imposing strict cash management rules including 90-day transfers to Axos Bank and balance limits on accounts such as Canadian Project Accounts ($15M aggregate) and Chanute Operating Account ($5M). The amendment mandates redemption of December 2026 Unsecured Notes by November 30, 2026, following prior full repayment of February 2026 Unsecured Notes, while noting entity name changes including B. Riley Financial, Inc. to BRC Group Holdings, Inc. and dissolutions of SOFCO-EFS Holdings LLC and B&W PGG Luxembourg Canada Holdings.

• ·Unrestricted cash outside Axos Bank capped at $15M aggregate, with no more than $5M in non-controlled accounts, Canadian Project Accounts, or Chanute Operating Account.
• ·Within 90 days of February 25, 2026, transfer substantially all USD deposits from Canadian Project Accounts and Chanute Operating Account to Axos Bank.
• ·Notice of redemption for December 2026 Unsecured Notes required by October 30, 2026, with full satisfaction by November 30, 2026.
• ·Aggregate balance of Chanute Operating Account and Canadian Project Accounts not to exceed $15M at any time.